Volume 96, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The prevalence of hepatitis B virus (HBV) in Wallis and Futuna (WAF) was one of the highest in the Pacific and was the driving factor for introducing hepatitis B (HepB) vaccination in 1992 and HepB birth dose (HepB-BD) in 2006. Using lymphatic filariasis (LF) transmission assessment survey (TAS) as a survey platform for eliminating LF, we assessed HBV surface antigen (HBsAg) seroprevalence, HepB vaccination coverage, and its timeliness among schoolchildren in WAF. From one finger prick of all registered fourth and fifth grade students, we tested HBsAg and filariasis antigen simultaneously, and estimated HepB vaccination coverage and timeliness by reviewing students' immunization cards. Since the children targeted were born when the three-dose HepB schedule was 2, 3, and 8 months, we defined timely vaccination if each dose was given by 3, 4, and 12 months. Of 476 targeted, 427 were enrolled. HBsAg prevalence was 0.9%. Estimated HepB vaccination coverage was 97%, 97%, and 96% for the first, second, and third doses, respectively, yielding coverage for all three doses of 96%. Proportion of timely vaccination was lower: 80%, 56%, and 65%, respectively, and less than 50% for all three doses combined. The seroprevalence of HBsAg among schoolchildren in WAF is less than 1%, close to the control goal. HepB vaccination coverage was high, but many children were vaccinated late. We recommend increasing the efforts for timely HepB vaccination. By combining an HBV seroprevalence survey and coverage assessment, we demonstrated the benefit of using TAS as a public health platform to access schoolchildren.


Article metrics loading...

Loading full text...

Full text loading...



  1. WHO Publication, 2010. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine 28: 589590.[Crossref]
  2. Hyams KC, , 1995. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 20: 9921000.[Crossref]
  3. Desalegn Z, Wassie L, Beyene HB, Mihret A, Ebstie YA, , 2016. Hepatitis B and human immunodeficiency virus co-infection among pregnant women in resource-limited high endemic setting, Addis Ababa, Ethiopia: implications for prevention and control measures. Eur J Med Res 21: 16.[Crossref]
  4. Alter MJ, , 2003. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39 (Suppl 1): S64S69.[Crossref]
  5. WHO, 2016. Hepatitis B. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed January 2, 2017.
  6. WHO/WPRO, 2013. Hepatitis B Control through Vaccination: Setting the Target. Session 7. Manila, Philippines: WHO/WPRO. Available at: http://www.wpro.who.int/about/regional_committee/64/documents/WPR_RC064_07_HepB_2013_en.pdf. Accessed May 26, 2016.
  7. WHO/WPRO, 2003. Expanded Programme on Immunization: Measles and Hepatitis B. WHO/WPRO Resolution 3. Manila, Philippines: WHO/WPRO. Available at: http://www2.wpro.who.int/rcm/en/archives/rc54/rc_resolutions/wpr_rc54_r03.htm. Accessed May 26, 2016.
  8. Rani M, , 2009. Hepatitis B control by 2012 in the WHO Western Pacific Region. Bull World Health Organ 87: 707713.[Crossref]
  9. Wong DC, Purcell RH, Rosen L, , 1979. Prevalence of antibody to hepatitis A and hepatitis B viruses in selected populations of the South Pacific. Am J Epidemiol 110: 227236.[Crossref]
  10. WHO/WPRO, 1999. Hepatitis and related diseases. WHO/WPRO Regional Committee. Macao, China: WHO/WPRO. Available at: http://http://iris.wpro.who.int/handle/10665.1/7400. Accessed May 26, 2016.
  11. Zanetti AR, Van Damme P, Shouval D, , 2008. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26: 62666273.[Crossref]
  12. Ni Y-H, Chen D-S, , 2010. Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol (Paris) 58: 296300.[Crossref]
  13. Bialek SR, Helgenberger L, Fischer GE, Bower WA, Konelios M, Chaine J-P, Armstrong G, Williams IT, Bell BP, , 2010. Impact of routine hepatitis B immunization on the prevalence of chronic hepatitis B virus infection in the Marshall Islands and the federated States of Micronesia. Pediatr Infect Dis J 29: 1822.[Crossref]
  14. Luo Z, Li L, Ruan B, , 2012. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 16: e82e88.[Crossref]
  15. SPC, Prism, 2016. Demographic Statistics: Pacific Statistics. Available at: http://prism.spc.int/regional-data-and-tools/population-statistics. Accessed May 26, 2016.
  16. WHO, 2011. Lymphatic Filariasis: Monitoring and Epidemiological Assessment of Mass Drug Administration. Available at: http://www.who.int/lymphatic_filariasis/resources/9789241501484/en/. Accessed May 26, 2016.
  17. Dayan GH, Shaw KM, Baughman AL, Orellana LC, Forlenza R, Ellis A, Chaui J, Kaplan S, Strebel P, , 2006. Assessment of delay in age-appropriate vaccination using survival analysis. Am J Epidemiol 163: 561570.[Crossref]
  18. Wilson N, Ruff TA, Rana BJ, Leydon J, Locarnini S, , 2000. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga, and Vanuatu. Vaccine 18: 30593066.[Crossref]
  19. Louis FJ, Morillon M, Boye B, Soullie B, Huerre M, Labrouasse R, Sapin C, Amouretti M, , 1992. Hepatitis B in Wallis: results of a seroepidemiological survey. Bull Soc Pathol Exot 85: 333337.
  20. Asia and Pacific Alliance to Eliminate Viral Hepatitis, 2013. Hepatitis B and C country profile, Wallis and Futuna, 2011. Available at: http://media.wix.com/ugd/c5881b_6e927b51d7824e5daa8869680ca65f12.pdf.
  21. Suárez-Castaneda E, Pezzoli L, Elas M, Baltrons R, Crespin-Elías EO, Pleitez OAR, de Campos MIQ, Danovaro-Holliday MC, , 2014. Routine childhood vaccination programme coverage, El Salvador, 2011—in search of timeliness. Vaccine 32: 437444.[Crossref]
  22. Tharmaphornpilas P, Rasdjarmrearnsook A, Plianpanich S, Sa-nguanmoo P, Poovorawan Y, , 2009. Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination. Vaccine 27: 61106115.[Crossref]
  23. Lankarani KB, , 2011. The necessity of booster vaccination after neonatal hepatitis B vaccination. Hepat Mon 11: 419421.
  24. Chu BK, Gass K, Batcho W, 'Ake M, Dorkenoo AM, Adjinacou E, Mafi 'E, Addiss DG, , 2014. Pilot assessment of soil-transmitted helminthiasis in the context of transmission assessment surveys for lymphatic filariasis in Benin and Tonga. PLoS Negl Trop Dis 8: e2708.[Crossref]
  25. Drabo F, Ouedraogo H, Bougma R, Bougouma C, Bamba I, Zongo D, Bagayan M, Barrett L, Yago-Wienne F, Palmer S, Chu B, Toubali E, Zhang Y, , 2016. Successful control of soil-transmitted helminthiasis in school age children in Burkina Faso and an example of community-based assessment via lymphatic filariasis transmission assessment survey. PLoS Negl Trop Dis 10: e0004707.[Crossref]
  26. WHO, 2011. Western Pacific Region Health Databank, 2011 Revision. Geneva, Switzerland: World Health Organization.
  27. Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Picard O, Nau J, Campa P, Silbermann B, Bary M, Girard P-M, Lacombe K, , 2013. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol 58: 473478.[Crossref]
  28. Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM, , 2012. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol 57: 515521.[Crossref]

Data & Media loading...

  • Received : 21 Jul 2016
  • Accepted : 21 Nov 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error